Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06789172 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Sarcoma, sponsored by Epkin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
- 10
- Study locations
NCT06789172 is a Phase 1 study of Non-Small Cell Lung Cancer and Sarcoma that is actively recruiting participants, run by Epkin. The registered enrollment target is 166 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT06789172, a Phase 1 study of Non-Small Cell Lung Cancer and Sarcoma, is actively recruiting participants, sponsored by Epkin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. This study will be split into 2 parts. Part 1a will look at multiple doses of OKN4395 either alone (monotherapy) or with pembrolizumab (combination therapy) administered on day 1 of each 21-day cycle in patients with solid tumors until the participant has disease progression or discontinues for any reason. The dose of OKN4395 will be increased, after each group of 3 or more patients completes their first 3 weeks of treatment and their data is evaluated for safety, with a planned dose range from 10 mg twice a day to 450 mg twice a day through 13 dose levels. Part 1b will evaluate OKN4395 alone and in combination with pembrolizumab administered on day 1 of each 21-day cycle in patients with selected cancer types. Part 1b will comprise 5 cohorts: Cohort 1 in sarcoma (OKN4395 alone), Cohort 2 pancreatic adenocarcinoma (OKN4395 alone), Cohort 3 in non-small cell lung cancer (NSCLC), Cohort 4 in colorectal cancer, and Cohort 5 in head \& neck squamous cell carcinoma (HNSCC), with cohorts 3 to 5 in combination with pembrolizumab. The monotherapy expansion Cohort 1 will also be used to explore the effect of food on the levels of OKN4395 in the blood. Similarly, Cohort 2 will be used to explore the effect of gastric pH on the levels of OKN4395 in the blood. The overall study will enrol approximately 166 participants with up to 54 participants to receive OKN4395 alone and 12 participants to receive OKN4395 in combination with pembrolizumab in Part 1a, and 100 participants in Part 1b split: 40 on mon
Conditions Studied
Interventions
- OTHER Fasting
- COMBINATION_PRODUCT Pembrolizumab
- DRUG H2 Receptor Antagonist
- DRUG OKN4395
- OTHER Fed
Study Locations (10)
Other
- The Beatson - Glasgow
- Leicester Royal Infirmary - Leicester
- University College London Hospital - London
- The Christie - Manchester
- Churchill Hospital - Oxford
California
- Precision NextGen Oncology and Research Center - Beverly Hills
- Sarcoma Oncology Center - Santa Monica
Texas
- MD Anderson Cancer Center - Houston
New South Wales
- Chris O'Brien Lifehouse - Sydney
Western Australia
- Linear Clinical Research - Perth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06789172
The ClinicalTrials.gov registry entry for NCT06789172 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Epkin, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fasting is the first listed.
NCT06789172 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06789172 about?
NCT06789172 is a clinical study titled "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors". The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combinat...
What is the current status of trial NCT06789172?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2025-01-23. Estimated completion is 2028-09.
What conditions does trial NCT06789172 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Sarcoma, Head and Neck Squamous Cell Carcinoma, NSCLC, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06789172?
The interventions under investigation include: Fasting (OTHER), Pembrolizumab (COMBINATION_PRODUCT), H2 Receptor Antagonist (DRUG), OKN4395 (DRUG), Fed (OTHER).
Who is sponsoring clinical trial NCT06789172?
This trial is sponsored by Epkin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06789172 being conducted?
This trial has 10 study locations across California, Texas, New South Wales, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.